Prestige Consumer Healthcare (NYSE:PBH) Hits New 12-Month Low - Should You Sell?

Key Points

• Prestige Consumer Healthcare's stock hit a new 12-month low at $61.04, closing at $61.40 on significant trading volume.
• Analyst ratings are mixed, with Sidoti upgrading the stock to a "buy" with a target price of $80.00, while Zacks downgraded it to a "strong sell."
• The company reported a quarterly EPS of $0.95, missing estimates and showing a 6.6% decline in revenue compared to last year.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) hit a new 52-week low on Friday . The stock traded as low as $61.04 and last traded at $61.40, with a volume of 84039 shares traded. The stock had previously closed at $62.79.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PBH. Sidoti raised Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 target price for the company in a research report on Wednesday, September 24th. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research note on Wednesday. Zacks Research cut Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Thursday, September 4th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Hold" and a consensus target price of $94.80.

Prestige Consumer Healthcare Price Performance

The company has a 50 day simple moving average of $65.53 and a 200-day simple moving average of $76.37. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of 14.41, a PEG ratio of 2.00 and a beta of 0.44. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company's quarterly revenue was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. grew its holdings in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company's stock worth $26,000 after buying an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock worth $26,000 after buying an additional 250 shares in the last quarter. Maseco LLP bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth approximately $27,000. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the 1st quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. grew its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.